BioXcel Therapeutics is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence.
BioXcel Therapeutics has raised $8.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
BioXcel Therapeutics's investors include Oaktree Capital Management, Qatar Investment Authority.
BioXcel Therapeutics is headquartered in New Haven, United States.
BioXcel Therapeutics is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence.
BioXcel Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioXcel Therapeutics — Funding & Investors." VCBacked, March 10, 2026, https://www.vcbacked.co/company/bioxcel-therapeutics. Accessed September 30, 2026.
VCBacked. (2026). BioXcel Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/bioxcel-therapeutics
{{cite web |title=BioXcel Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/bioxcel-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated